Opinion|Videos|July 29, 2024
Adverse Events with EMAs: Luspatercept
Author(s)Guillermo Garcia-Manero, MD
Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss the adverse events profile associated with luspatercept for any grade and ≥ grade 3 AEs.
- Which AEs are most concerning? Are hematologic or non-hematologic most common?
- How do you manage these events in your practice? Do the AEs have a significant impact on quality of life for patients?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5